Pharma Marketletter

Click on article title to view & purchase. Articles are sorted by their publication date in reverse chronological order.

Abbott's humira is cleared in the EU as a therapy for rheumatoid arthr...
September 22, 2003

Genaissance signs deal with AstraZeneca.
September 22, 2003

InNexus and Corixa enter antibody collab.
September 22, 2003

Nymox to file up to four INDs within 12 months.
September 22, 2003

Forsythe launches new biotecc subsidiary.
September 22, 2003

Xoma plans nine million share offering.
September 22, 2003

Mylan gets FDA appro for generic midodrine.
September 22, 2003

Eon to commence shipping of Shire generic.
September 22, 2003

HRT sales to plummet, osteoporosis market to benefit?
September 22, 2003

Orion Clinical Services opens new UK headquarters.
September 22, 2003

Prana Biotech raises A$5 million.
September 22, 2003

Pfizer India hiving off older drugs.
September 22, 2003

Tanabe Seiyaku to increase R&D staff and spending.
September 22, 2003

Wyeth to boost sales 60% in Japan with new drug launches.
September 22, 2003

Terumo forecasts over 50% profit margin in the fiscal year 2004.
September 22, 2003

AnGes to raise 5.4 billion yen via IPO.
September 22, 2003

PPL Therapeutics to sell business after key investors lose faith.
September 22, 2003

First biotech IPO of 2003 making progress.
September 22, 2003

EU anger as WTO Cancun talks fail.
September 22, 2003

New EU states' fears over data protection.
September 22, 2003

ECoJ Opinion backs parallel importers.
September 22, 2003

Promising Ph III data for DOV's bicifadine.
September 22, 2003

Multi-dose safety trial for Rigel's R112 begins.
September 22, 2003

Positive data for NicOx' NCX-4016.
September 22, 2003

Pierre Fabre's Javlor enters Ph III trials.
September 22, 2003

German panel doctors paying more to their national body.
September 22, 2003

French CNAM backs consultant fee rise.
September 22, 2003

France unveils hospital modernization plan.
September 22, 2003

US FDA calls on pharma for anti-radiation NDAs.
September 22, 2003

Illinois drafts Canadian Rx-buying plan.
September 22, 2003

US insurers move on generics, OTCs.
September 22, 2003

US Justice Dept files against Rx Depot.
September 22, 2003

Ligand raises $47M in private placing.
September 22, 2003

Gilead buys Foster City campus for $123M.
September 22, 2003

Xention completes L4M placing.
September 22, 2003

Oncolytics forms scientific advisory board.
September 22, 2003

Tokyo pharma stocks - week to Sept 15.
September 22, 2003

New operational structure at Aventis.
September 22, 2003

MediGene's shares leap on patent announcement.
September 22, 2003

$100,000 SBIR grant for BioSante.
September 22, 2003

Sanitas of Lithuania sees sales leap 14%.
September 22, 2003

BioXell recruits Meenu Chhabra a director of business development.
September 22, 2003

Michael Schultz joins Bayer as VP, strategic project management.
September 22, 2003

Peter Ballie joins IsoTis as VP marketing & Sales, EMEA/AP.
September 22, 2003

John Keller joins Incyte as VP and chief business officer.
September 22, 2003

GPhA names Bruce Lott senior director of state affairs.
September 22, 2003

Czech drugmaker Spofa records loss for 2002.
September 22, 2003

Cubist's antibiotic cleared by FDA.
September 22, 2003

Novartis' Prexige gets first EU approval.
September 22, 2003

Alpharma surges as FDA approves generic.
September 22, 2003

EC OKs new use for Genzyme's Cerezyme.
September 22, 2003

Merck & Co bids for remainder of Banyu.
September 22, 2003

P&G plans large Prilosec debut in USA.
September 22, 2003

Alpharma lowers forecasts, shares slide.
September 22, 2003

Eyetech files for $100M biotech IPO.
September 22, 2003

Boeh-Ing investment.
September 22, 2003

Onyx/Oryx correction.
September 22, 2003

Spanish consumer drug prices in August.
September 22, 2003

Spain's new Rx reference price scheme "will strangle R&D and cut profi...
September 22, 2003

US FDA seizes "potentially dangerous" drugs from repackager.
September 22, 2003

US NABP slams AIDS Drugs Direct claims.
September 22, 2003

Wyeth secrets were stolen, says judge.
September 22, 2003

Acambis CEO steps down, despite success; results on track in first hal...
September 22, 2003

Cyanotech appeals Nasdaq delisting.
September 22, 2003

Genzyme completes $600M SangStat deal.
September 22, 2003

Omega could top full year forecasts.
September 22, 2003

Logic of in-house drug development vs in-licensing, as assessed by Mer...
September 22, 2003

Boeh Ingelheim opens new 255M-euro facility.
September 22, 2003

Endo Pharma converting to own sales reps.
September 22, 2003

Scynexis and Roche expand deal.
September 22, 2003

Sankyo's Benicar HCT launched in USA.
September 22, 2003

Aventis' Arava now available in Japan.
September 22, 2003

Kaletra shows long-term benefits in HIV.
September 22, 2003

Promising new data on Shire/J&J's Reminyl.
September 22, 2003

UK NICE has "inherent contradiction" over transparency, data confident...
September 22, 2003

Page 1|2|3|4|5|6